Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
HRTX

HRTX - Heron Therapeutics Inc Stock Price, Fair Value and News

$0.40-0.01 (-2.44%)
Market Closed as of 12 Jun 2026, 04:00 pm ET

51/100

HRTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

51/100

HRTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

HRTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HRTX Price Action

Last 7 days

-7.0%

Last 30 days

-56.0%

Last 90 days

-54.5%

Trailing 12 Months

-80.1%

HRTX RSI Chart

HRTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HRTX Valuation

Market Cap

75.9M

Price/Earnings (Trailing)

-2.45

Price/Sales (Trailing)

0.5

EV/EBITDA

-86.61

Price/Free Cashflow

-3.64

HRTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

HRTX Fundamentals

HRTX Revenue

Revenue (TTM)

150.7M

Rev. Growth (Yr)

-10.78%

Rev. Growth (Qtr)

-14.48%

HRTX Earnings

Earnings (TTM)

-30.9M

Earnings Growth (Yr)

-407.82%

Earnings Growth (Qtr)

-174.58%

HRTX Profitability

EBT Margin

-7.59%

Return on Equity

-338.63%

Return on Assets

-12.57%

Free Cashflow Yield

-27.5%

HRTX Investor Care

Shares Dilution (1Y)

23.56%

Diluted EPS (TTM)

-0.17

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2026150.7M000
2025148.5M149.7M155.1M154.9M
2024132.1M136.4M137.7M144.3M
2023113.8M118.0M122.8M127.0M
202289.8M95.0M98.3M107.7M
202183.3M83.1M86.3M86.3M
2020139.8M125.8M103.2M88.7M
201997.5M116.9M139.7M146.0M
201838.7M47.5M58.7M77.5M
20178.7M16.0M23.4M30.8M
20160000
20150000
20140000
20130000
20120000
20110973.5K809.8K646.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Heron Therapeutics Inc

HRTX
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
 CEO
 WEBSITEherontx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES203

Heron Therapeutics Inc Frequently Asked Questions

HRTX is the stock ticker symbol of Heron Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jun 12 2026, market cap of Heron Therapeutics Inc is 75.86 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jun 12 2026, HRTX's PE ratio (Price to Earnings) is -2.45 and Price to Sales (PS) ratio is 0.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HRTX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Heron Therapeutics Inc has provided -0.317 (multiply by 100 for percentage) rate of return.